Bristol-Myers Squibb Co. (BMY)
What changed in recent filings
- Revenue +6% YoYQuarter ended Jun 30, 2026
- Institutions — 1 new · 2 added · 1 reduced13F · as of end of 2026 Q2
What changed in recent SEC filings — factual, not a buy/sell recommendation.
Bristol-Myers Squibb Co. recent earnings releases
Based on SEC filings. The release date is the day the earnings filing (8-K) was accepted; for quarters where that filing was not found, the periodic report filing date is shown.
- 26Q2Released Jul 30, 2026Revenue +5.7% YoY · EPS $1.62Released before the open: Jul 29 close → Jul 30 close, the stock moved +2.8% · over the same window, market +1.7% · sector -0.9%
- 26Q1Released Apr 30, 2026Revenue +2.6% YoY · EPS $1.31Released before the open: Apr 29 close → Apr 30 close, the stock moved +5.2% · over the same window, market +1.0% · sector +1.0%
- 25Q4Released Feb 5, 2026Revenue +1.3% YoY · EPS $0.53Released before the open: Feb 4 close → Feb 5 close, the stock moved +3.3% · over the same window, market -1.2% · sector -0.4%
- 25Q3Released Oct 30, 2025Revenue +2.8% YoY · EPS $1.08Released before the open: Oct 29 close → Oct 30 close, the stock moved +7.1% · over the same window, market -1.1% · sector +0.0%
The next earnings release is estimated around Oct 29, 2026 (calculated from how long this company has taken between quarter end and filing; it is not a date announced by the company).
Institutions holding Bristol-Myers Squibb Co.
How many of the institutions we track reported holding this stock, quarter by quarter.
2019 Q1: 12 → 2026 Q2: 8 institutions
Counts the 52 institutions we track that reported holding this stock — their full reported holdings, not just the largest positions. Not the total number of institutional holders in the US. Figures are as of quarter-end and disclosed up to 45 days later. Descriptive only — not investment advice.
Which institutions hold Bristol-Myers Squibb Co.
Institutions we track that reported holding this stock in their most recent 13F.
- National Pension Service (Korea)0.21% of portfolio · held as of 2019 Q1 or earlier
- Dodge & Coxunder 0.01% of portfolio · held as of 2019 Q1 or earlier
- PRIMECAP Management0.85% of portfolio · held as of 2019 Q1 or earlier
- Caisse de depot (Quebec)0.35% of portfolio · held as of 2019 Q1 or earlier
- Pzena Investment Management2.88% of portfolio · since 2019 Q3
- GQG Partners0.01% of portfolio · since 2026 Q1
- Capital World Investors0.02% of portfolio · since 2026 Q1
- BlackstoneNew this quarterunder 0.01% of portfolio · since 2026 Q2
Based on 13F filings — quarter-end holdings, disclosed up to 45 days later. Holding a stock is a fact we report, not a recommendation to buy or sell.
Q2 2026 13F recap — stocks several institutions bought and sold together →Company overview
Bristol-Myers Squibb Company is a global biopharmaceutical company that discovers, develops, manufactures, and commercializes medicines for serious diseases. Bristol-Myers Squibb Company focuses on major therapeutic areas including oncology, hematology, immunology, cardiovascular disease, and neuroscience, serving patients with complex and often chronic conditions. Its portfolio includes small-molecule drugs, biologics, and cell therapies, reflecting a broad approach to advanced treatment design and delivery. The company supports healthcare systems through research-driven products used in hospitals, specialty clinics, and outpatient care settings around the world. Bristol-Myers Squibb Company plays an important role in the pharmaceutical market by providing therapies aimed at difficult-to-treat illnesses and by maintaining a diversified pipeline and product mix across multiple disease categories.
What is the Biotech & Health sector?
Pharma, biotech, and medical devices. Driven by trial-result events.
Bristol-Myers Squibb Co. is classified under the Biotech & Health sector. See peers below.
Bristol-Myers Squibb Co. key financials
Based on SEC filings · as of Jun 30, 2026
Tap a metric name to see its meaning in the glossary.
Bristol-Myers Squibb Co. vs Biotech & Health sector benchmark
Median of 38 representative sector stocks · SEC filings · factual comparison (not advice)
A simple comparison to the sector benchmark. Higher or lower doesn’t mean good/bad or buy/sell.
BMY revenue by segment summary
SEC 10-Q · segment totals cross-checked against total revenue
2026-06-30 revenue was $13.0B, +5.7% YoY.
The largest segment is US, 69.3% of revenue — a highly concentrated structure.
Recent revenue growth was led mainly by the US segment (about 67% of the increase).
Full segment weights, YoY changes, and an AI synthesis are available in the detailed analysis.
BMY segment revenue mix trend
Quarterly change in segment revenue share · verified from SEC filings
ETFs holding Bristol-Myers Squibb Co.
Per SEC N-PORT · 2026-05-31 · by weight · factual
BMY on Stocklore
- Revenue by segment — segment weights verified from SEC filings, YoY changes, growth drivers and concentration
- Financials & earnings quality — 6 metrics (FCF conversion, ROIC, net debt, etc.) to gauge profit quality
- 13F institutional holdings — holdings and weight changes of major institutions (45-day delay)
- Sector-relative metrics — Valuation and growth compared with the Biotech & Health average
Peers · Biotech & Health
BMY FAQ
What is Bristol-Myers Squibb Co. (BMY)?
Bristol-Myers Squibb Company is a global biopharmaceutical company that discovers, develops, manufactures, and commercializes medicines for serious diseases. Bristol-Myers Squibb Company focuses on major therapeutic areas including oncology, hematology, immunology, cardiovascular disease, and neuroscience, serving patients with complex and often chronic conditions. Its portfolio includes small-molecule drugs, biologics, and cell therapies, reflecting a broad approach to advanced treatment design and delivery. The company supports healthcare systems through research-driven products used in hospitals, specialty clinics, and outpatient care settings around the world. Bristol-Myers Squibb Company plays an important role in the pharmaceutical market by providing therapies aimed at difficult-to-treat illnesses and by maintaining a diversified pipeline and product mix across multiple disease categories.
What sector is Bristol-Myers Squibb Co. in?
Bristol-Myers Squibb Co. is classified under Biotech & Health. Pharma, biotech, and medical devices. Driven by trial-result events.
What are Bristol-Myers Squibb Co.'s key financials?
As of Jun 30, 2026 in SEC filings: Revenue growth (YoY) 3.1%, Net margin 18.9%, ROE 38.2%, Debt-to-equity 1.92x. Definitions and interpretation are available on Stocklore.
What are Bristol-Myers Squibb Co.'s main revenue segments?
The largest segment is US, about 69.3% of revenue. Segment totals are cross-checked against total revenue from SEC filings.
Where can I analyze Bristol-Myers Squibb Co. (BMY) stock?
On Stocklore you can see BMY's financials & earnings quality, 13F institutional holdings, and sector-relative metrics in one place. This page is for information and tools — not a buy/sell recommendation.
Data sources: SEC EDGAR (financials & filings), 13F (institutional holdings, as of quarter-end), market data. This page is for information and analysis tools — it does not recommend buying or selling any security. Investment decisions and responsibility are your own.